文献速递慢性肾脏病

维生素D受体激活与限钠对CKD残余白蛋白尿的影响:ViRTUE-CKD试验

Effects of Vitamin D Receptor Activation and Dietary Sodium Restriction on Residual Albuminuria in CKD: The ViRTUE-CKD Trial.
PubMed 文献 · J Am Soc Nephrol · 2016-11-17

该多中心随机安慰剂对照交叉试验纳入45例非糖尿病CKD 1-3期患者,在雷米普利10 mg/d且血压<140/90 mmHg下白蛋白尿仍>300 mg/24 h,比较帕立骨化醇与安慰剂分别联合低钠或常规钠饮食对残余白蛋白尿的影响。限钠显著降低白蛋白尿,帕立骨化醇额外效应小且未达统计学显著。

要点

  • 常规钠+安慰剂时白蛋白尿几何均值为1060 mg/24 h,常规钠+帕立骨化醇为990 mg/24 h(P=0.20)。
  • 低钠+安慰剂降至717 mg/24 h,低钠+帕立骨化醇降至683 mg/24 h,均较常规钠+安慰剂P<0.001。
  • 帕立骨化醇在限钠基础上的额外降低未达统计学显著(P=0.60)。

核心结论

  • 在固定剂量ACE抑制下,适度限钠可大幅降低CKD患者的残余白蛋白尿,帕立骨化醇的额外效应小且未达统计学显著。

研究设计与样本

  • 多中心、随机、安慰剂对照、交叉试验,纳入45例非糖尿病CKD 1-3期且白蛋白尿>300 mg/24 h的患者。
  • 患者接受四个8周周期,分别为帕立骨化醇(2 μg/d)或安慰剂,各联合低钠或常规钠饮食。
  • 采用线性混合效应模型分析重复测量数据。

主要发现

  • 意向性分析中,常规钠+安慰剂时白蛋白尿几何均值为1060(95%CI 778-1443)mg/24 h,常规钠+帕立骨化醇为990(95%CI 755-1299)mg/24 h(P=0.20)。
  • 低钠+安慰剂降至717(95%CI 512-1005)mg/24 h(P<0.001 vs 常规钠+安慰剂),低钠+帕立骨化醇降至683(95%CI 502-929)mg/24 h(P<0.001 vs 常规钠+安慰剂)。
  • 帕立骨化醇在限钠基础上的额外降低未达统计学显著(P=0.60)。
  • 符合方案分析限于研究药物依从性≥95%的参与者,低钠+帕立骨化醇较低钠+安慰剂进一步降低白蛋白尿(P=0.04)。
  • 联合常规钠组尿钠排泄为174±64 mmol/d,低钠组为108±61 mmol/d(P<0.001)。

临床怎么用

  • 原文结论未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Reduction of residual albuminuria during single-agent renin-angiotensin-aldosterone blockade is accompanied by improved cardiorenal outcomes in CKD. We studied the individual and combined effects of the vitamin D receptor activator paricalcitol (PARI) and dietary sodium restriction on residual albuminuria in CKD. In a multicenter, randomized, placebo (PLAC)-controlled, crossover trial, 45 patients with nondiabetic CKD stages 1-3 and albuminuria >300 mg/24 h despite ramipril at 10 mg/d and BP<140/90 mmHg were treated for four 8-week periods with PARI (2 μg/d) or PLAC, each combined with a low-sodium (LS) or regular sodium (RS) diet. We analyzed the treatment effect by linear mixed effect models for repeated measurements. In the intention-to-treat analysis, albuminuria (geometric mean) was 1060 (95% confidence interval, 778 to 1443) mg/24 h during RS + PLAC and 990 (95% confidence interval, 755 to 1299) mg/24 h during RS + PARI (P=0.20 versus RS + PLAC). LS + PLAC reduced albuminuria to 717 (95% confidence interval, 512 to 1005) mg/24 h (P<0.001 versus RS + PLAC), and LS + PARI reduced albuminuria to 683 (95% confidence interval, 502 to 929) mg/24 h (P<0.001 versus RS + PLAC). The reduction by PARI beyond the effect of LS was nonsignificant (P=0.60). In the per-protocol analysis restricted to participants with ≥95% compliance with study medication, PARI did provide further albuminuria reduction (P=0.04 LS + PARI versus LS + PLAC). Dietary adherence was good as reflected by urinary excretion of 174±64 mmol Na+ per day in the combined RS groups and 108±61 mmol Na+ per day in the LS groups (P<0.001). In conclusion, moderate dietary sodium restriction substantially reduced residual albuminuria during fixed dose angiotensin-converting enzyme inhibition. The additional effect of PARI was small and nonsignificant.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Keyzer CA, van Breda GF, Vervloet MG, et al. Effects of Vitamin D Receptor Activation and Dietary Sodium Restriction on Residual Albuminuria in CKD: The ViRTUE-CKD Trial. J Am Soc Nephrol. 2016. PMID: 27856633. doi:10.1681/ASN.2016040407

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。